1. Home
  2. PAVS vs ENTX Comparison

PAVS vs ENTX Comparison

Compare PAVS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paranovus Entertainment Technology Ltd.

PAVS

Paranovus Entertainment Technology Ltd.

HOLD

Current Price

$0.91

Market Cap

1.2M

Sector

Health Care

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.21

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAVS
ENTX
Founded
2004
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2M
62.6M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
PAVS
ENTX
Price
$0.91
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
58.7K
85.4K
Earning Date
07-31-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$17.43
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.91
52 Week High
$3.83
$3.22

Technical Indicators

Market Signals
Indicator
PAVS
ENTX
Relative Strength Index (RSI) 35.47 48.78
Support Level $0.67 $1.17
Resistance Level $1.17 $1.37
Average True Range (ATR) 0.09 0.07
MACD -0.01 -0.00
Stochastic Oscillator 9.27 21.05

Price Performance

Historical Comparison
PAVS
ENTX

About PAVS Paranovus Entertainment Technology Ltd.

Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: